Compare HYPR & RBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYPR | RBOT |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.9M | 17.9M |
| IPO Year | 2021 | N/A |
| Metric | HYPR | RBOT |
|---|---|---|
| Price | $1.05 | $2.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $1.28 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 297.8K | 61.7K |
| Earning Date | 04-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,890,000.00 | N/A |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $34.43 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.84 | N/A |
| 52 Week Low | $0.53 | $1.71 |
| 52 Week High | $2.22 | $13.75 |
| Indicator | HYPR | RBOT |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 45.38 |
| Support Level | $0.88 | $1.76 |
| Resistance Level | $1.19 | $2.41 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 17.14 | 38.63 |
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.